Published in Ann Neurol on May 01, 1996
Altered neuronal activity relationships between the pedunculopontine nucleus and motor cortex in a rodent model of Parkinson's disease. Exp Neurol (2008) 1.63
Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology (2011) 1.21
Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements. J Neurosci (2008) 1.19
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J (2007) 1.11
Differences in excitatory transmission between thalamic and cortical afferents to single spiny efferent neurons of rat dorsal striatum. Eur J Neurosci (2008) 0.98
Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease. Neurobiol Aging (2006) 0.97
Modeling Parkinson's disease in monkeys for translational studies, a critical analysis. Exp Neurol (2013) 0.94
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology (Berl) (2009) 0.86
Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates. Ann Neurol (2004) 0.85
Neurodegenerative Shielding by Curcumin and Its Derivatives on Brain Lesions Induced by 6-OHDA Model of Parkinson's Disease in Albino Wistar Rats. Cardiovasc Psychiatry Neurol (2012) 0.83
Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinsons Dis (2013) 0.82
Therapy for Parkinson's disease: what is in the pipeline? Neurotherapeutics (2014) 0.81
Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats. Brain Res (2003) 0.81
NMDA receptors in the basal ganglia. J Anat (2000) 0.80
Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications. Neuropharmacology (2014) 0.79
The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease. Psychopharmacology (Berl) (2014) 0.79
Involuntary movements during thermolesion predict a better outcome after microelectrode guided posteroventral pallidotomy. J Neurol Neurosurg Psychiatry (1997) 0.79
Quantitative autoradiographic study on receptor regulation in the basal ganglia in rat model of levodopa-induced motor complications. J Huazhong Univ Sci Technolog Med Sci (2009) 0.79
Pharmacological pallidotomy with glutamate antagonists. Ann Neurol (1996) 0.78
Striatal glutamate release in L-DOPA-induced dyskinetic animals. PLoS One (2013) 0.78
Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scale. J Neurosci Methods (2013) 0.78
Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias. Psychopharmacology (Berl) (2006) 0.78
Dopamine regulates distinctively the activity patterns of striatal output neurons in advanced parkinsonian primates. J Neurophysiol (2014) 0.78
NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and β-arrestin-1 expression in parkinsonian rats. Clin Interv Aging (2013) 0.78
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. PLoS One (2013) 0.76
Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum. Basal Ganglia (2012) 0.76
A placebo-controlled trial of dextromethorphan as an adjunct in opioid-dependent patients undergoing methadone maintenance treatment. Int J Neuropsychopharmacol (2015) 0.76
Non-human primate FOG develops with advanced parkinsonism induced by MPTP Treatment. Exp Neurol (2012) 0.75
Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates. Neurosci Bull (2015) 0.75
Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model. Oncotarget (2016) 0.75
Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile. Neuropharmacology (2016) 0.75
A new quantitative rating scale for dyskinesia in nonhuman primates. Behav Pharmacol (2015) 0.75
An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease. Oncotarget (2017) 0.75
The Mechanisms of Traditional Chinese Medicine Underlying the Prevention and Treatment of Parkinson's Disease. Front Pharmacol (2017) 0.75
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol (1998) 9.33
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (1990) 8.07
Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology (1983) 2.20
On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology (1975) 1.96
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology (1998) 1.96
Degradation of alpha-synuclein by proteasome. J Biol Chem (1999) 1.87
Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry (1992) 1.76
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol (2003) 1.75
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord (1998) 1.63
CFS hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry (1980) 1.59
Cortical abnormalities in Alzheimer's disease. Ann Neurol (1984) 1.57
D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science (1987) 1.49
L-Dopa-induced release of cerebral monoamines. Science (1970) 1.47
Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther (1970) 1.46
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology (1997) 1.46
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology (2003) 1.46
Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology (1997) 1.42
Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology (1992) 1.41
Milacemide therapy for Parkinson's disease. Mov Disord (1993) 1.38
Metabolism of tyramine-3H and octopamine-3H by rat brain. Biochem Pharmacol (1969) 1.35
Clinical and electroencephalographic manifestations of vascular lesions of the pons. Neurology (1968) 1.30
Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol (1987) 1.29
Towards a behavioral typology of Alzheimer's patients. J Clin Exp Neuropsychol (1986) 1.29
Stimulus-induced release of substances from olfactory bulb using the push-pull cannula. Nature (1968) 1.26
Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J Neurosci (1999) 1.25
Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. Neurology (1988) 1.19
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol (1988) 1.19
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology (2001) 1.15
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol (1990) 1.13
Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid. Neurology (1976) 1.11
Magnetic resonance imaging in Huntington disease. AJNR Am J Neuroradiol (1986) 1.10
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol (1988) 1.10
Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology (1996) 1.10
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology (1992) 1.08
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol (1987) 1.07
Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Ann Neurol (1984) 1.07
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res (1994) 1.05
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol (1999) 1.05
Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J (2004) 1.05
Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol (1989) 1.04
Structural and functional studies of Gilles de la Tourette syndrome. Rev Neurol (Paris) (1986) 1.04
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord (2001) 1.03
The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology (1993) 1.03
Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism. Lancet (1970) 1.03
Effect of ions on stimulus-induced release of amino acids from mammalian brain slices. J Neurochem (1969) 1.03
Frontal lobe function in progressive supranuclear palsy. Arch Neurol (1990) 1.02
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology (2002) 1.02
The functional neuroanatomy of Tourette's syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology (2002) 1.02
Dietary regulation of brain tryptophan metabolism by plasma ratio of free tryptophan and neutral amino acids in humans. Nature (1974) 1.02
Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease. Mov Disord (1992) 1.00
Serotonin and central nervous system function. Annu Rev Pharmacol (1973) 0.99
Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm. J Biol Chem (2001) 0.99
Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. J Neurol Neurosurg Psychiatry (1991) 0.98
Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther (1999) 0.98
Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders. Neuropharmacology (1970) 0.98
Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology (1999) 0.97
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology (2003) 0.97
Effect of L-DOPA on depression. Lancet (1969) 0.97
Neurohumoral mechanisms in the brain slice. Adv Pharmacol Chemother (1970) 0.97
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol (2005) 0.97
Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor. Lancet (1971) 0.96
A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system. Peptides (1985) 0.96
Muscimol: GABA agonist therapy in schizophrenia. Am J Psychiatry (1978) 0.95
The D1 dopamine receptor in the rat brain: quantitative autoradiographic localization using an iodinated ligand. Neuroscience (1988) 0.95
Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. J Neurol Neurosurg Psychiatry (1992) 0.94
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology (2004) 0.94
Nuclear factor-kappa B contributes to excitotoxin-induced apoptosis in rat striatum. Mol Pharmacol (1998) 0.94
Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid. J Neurochem (1973) 0.93
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord (1994) 0.93
Effect of diazepam on fate of intracisternally injected serotonin-C14. Neuropharmacology (1970) 0.92
Serotonin release from brain slices by electrical stimulation: regional differences and effect of LSD. Science (1967) 0.92
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology (2000) 0.92
Metabolism of some phenylethylamines and their beta-hydroxylated analogs in brain. J Pharmacol Exp Ther (1969) 0.92
Visuospatial cognition in Huntington's disease. Mov Disord (1991) 0.92
Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology (1991) 0.92
Quantitative autoradiographic localization of D-1 dopamine receptors in the rat brain: use of the iodinated ligand [125I]SCH 23982. Neurosci Lett (1986) 0.92
Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology (1987) 0.92
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology (1993) 0.91
Cognitive concomitants of dopamine system stimulation in parkinsonian patients. J Neurol Neurosurg Psychiatry (1987) 0.91
Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol (1987) 0.91
Release of ( 3 H)dopamine by L-5-hydroxytryptophan. Brain Res (1972) 0.91
Amyotrophic lateral sclerosis. A study of central monoamine metabolism and therapeutic trial of levodopa. Arch Neurol (1971) 0.91
Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol (1986) 0.91
Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation. J Neurochem (2000) 0.90
Autoradiographic distribution of substance P receptors in rat central nervous system. Nature (1983) 0.90
Release of [3H]serotonin from brain slices. J Neurochem (1969) 0.90
Wechsler Adult Intelligence Scale performance. Cortical localization by fluorodeoxyglucose F 18-positron emission tomography. Arch Neurol (1984) 0.90
A role for bombesin in sensory processing in the spinal cord. J Neurosci (1984) 0.89
Functional neuroanatomy of Tourette syndrome. Limbic-motor interactions studied with FDG PET. Adv Neurol (1992) 0.89
Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res (1999) 0.89
Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol (1994) 0.88
Diffuse involvement in progressive aphasia. Ann Neurol (1983) 0.88
5-hydroxyindoleacetic cid in spinal fluid: relative contribution from brain and spinal cord. Brain Res (1973) 0.88
Overexpression of neurotrophin receptor p75 contributes to the excitotoxin-induced cholinergic neuronal death in rat basal forebrain. Brain Res (2000) 0.88
Dopamine: stimulation-induced release from central neurons. Science (1971) 0.88
Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res (1998) 0.87
Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86. Arch Neurol (1986) 0.87
5-hydroxytryptophan in parkinsonism. Lancet (1970) 0.87
The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease. Biol Psychiatry (1991) 0.87
Depressed monoamine catabolite levels in cerebrospinal fluid of patients with parkinsonism dementia of Guam. N Engl J Med (1970) 0.86